Eli Lilly and Company, UnitedHealth Group, Johnson & Johnson, AbbVie, Amgen, Merck & Co., Inc., and Moderna are the seven Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of publicly traded companies that provide healthcare products or services, such as pharmaceutical and biotechnology firms, medical-device makers, hospitals, and health insurers. For investors, these stocks offer exposure to the healthcare industry, whose performance can be influenced by factors such as medical innovation, regulation, drug approvals, and demand for care. These companies had the highest dollar trading volume of any Healthcare stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
NYSE:LLY traded down $4.72 during trading hours on Friday, hitting $1,346.40. The company's stock had a trading volume of 3,539,886 shares, compared to its average volume of 3,049,248. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,475.25. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The stock has a fifty day simple moving average of $1,268.06 and a 200-day simple moving average of $1,119.25. The company has a market capitalization of $1.27 trillion, a P/E ratio of 43.70, a PEG ratio of 1.71 and a beta of 0.40.
Read Our Latest Research Report on LLY
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
UNH traded up $9.44 on Friday, reaching $339.92. The stock had a trading volume of 12,761,683 shares, compared to its average volume of 4,902,234. The firm has a 50-day moving average of $388.64 and a 200-day moving average of $367.55. The company has a market capitalization of $304.57 billion, a price-to-earnings ratio of 19.41, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51. UnitedHealth Group has a fifty-two week low of $255.96 and a fifty-two week high of $461.62. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of 0.66.
Read Our Latest Research Report on UNH
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
NYSE JNJ traded up $3.40 on Friday, hitting $270.54. The company's stock had a trading volume of 11,918,705 shares, compared to its average volume of 7,422,689. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $199.90 and a 1-year high of $290.25. The company's 50-day moving average is $267.53 and its 200 day moving average is $250.98. The firm has a market cap of $651.27 billion, a PE ratio of 40.99, a PEG ratio of 2.79 and a beta of 0.22.
Read Our Latest Research Report on JNJ
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of NYSE:ABBV traded up $2.65 during mid-day trading on Friday, reaching $286.19. 8,754,855 shares of the company's stock were exchanged, compared to its average volume of 5,219,851. The firm has a market capitalization of $505.88 billion, a price-to-earnings ratio of 49.26, a PEG ratio of 1.34 and a beta of 0.20. The business's fifty day moving average price is $278.98 and its 200-day moving average price is $242.55. AbbVie has a twelve month low of $190.75 and a twelve month high of $302.93.
Read Our Latest Research Report on ABBV
Amgen (AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
NASDAQ:AMGN traded down $3.30 during trading hours on Friday, hitting $435.52. 4,942,211 shares of the company were exchanged, compared to its average volume of 2,659,914. The stock has a market capitalization of $235.58 billion, a price-to-earnings ratio of 25.26, a price-to-earnings-growth ratio of 3.22 and a beta of 0.43. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. Amgen has a one year low of $312.39 and a one year high of $483.99. The company has a fifty day simple moving average of $430.44 and a 200 day simple moving average of $383.81.
Read Our Latest Research Report on AMGN
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Shares of NYSE MRK traded up $0.75 during trading on Friday, reaching $133.56. The company had a trading volume of 15,606,219 shares, compared to its average volume of 9,559,102. The company's fifty day moving average price is $145.28 and its 200-day moving average price is $129.29. Merck & Co., Inc. has a 12 month low of $95.36 and a 12 month high of $156.92. The stock has a market cap of $329.26 billion, a P/E ratio of 137.69, a PEG ratio of 6.62 and a beta of 0.13. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.
Read Our Latest Research Report on MRK
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
MRNA stock traded down $5.15 during trading on Friday, hitting $194.18. The company had a trading volume of 9,660,060 shares, compared to its average volume of 14,268,253. The business has a 50-day moving average of $207.87 and a 200-day moving average of $100.37. Moderna has a one year low of $22.28 and a one year high of $280.80. The stock has a market cap of $78.57 billion, a PE ratio of -27.35 and a beta of 1.16. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52.
Read Our Latest Research Report on MRNA
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.